NCT07163507Not yet recruiting
Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples
Source: ClinicalTrials.gov · Last updated 18 Mar 2026
Brief summary (registry, in English)
Lung cancer is the leading cause of cancer-related death worldwide, with nearly 2.48 million cases and 1.8 million deaths in 2022. Despite therapeutic progress, late diagnosis and high mortality make it a major public health issue. Immune checkpoint inhibitors (ICI) such as nivolumab, pembrolizumab, and atezolizumab have improved outcomes for some patients, but only a small proportion benefit, and side effects can be severe. Research is focusing on combining ICIs with chemotherapy, radiotherapy, or other immunotherapies, but reliable biomarkers to predict responders are still lacking. The tumor microenvironment, which promotes resistance, is a promising therapeutic target. The RICEPS study (2021-2023) found specific immune cells and cytokines linked to treatment response, and the ongoing RICEPS-2 trial aims to confirm these findings in a larger group to better understand immune dynamics in lung cancer under ICI therapy.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 1 Sept 2025
- Start date
- Apr 2026
- Primary completion date
- Oct 2028
- Lead sponsor
- University Hospital, Tours
- Diseases
- Lung cancer
- NCT number
- NCT07163507
What you commit to
- Study type: Interventional
- Planned participants: 50
- From Apr 2026 to the primary completion date, Oct 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Pregnant or breastfeeding women
- Individuals under guardianship, conservatorship, or judicial protection, or in a situation of deprivation of liberty
Who the study is looking for
- . Age 18 years or older
- Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC)
- Requiring initiation of treatment with anti-PD1 or anti-PDL1 ICI (nivolumab, pembrolizumab, atezolizumab, durvalumab, cemiplimab), with or without chemotherapy
- Never having received ICI treatment
- Affiliated with a social security system
- Having signed a written, free, and informed consent form
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| university hospital, Tours Coordinator of this site? Confirm its status | Tours | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.